enGene reports Q3 2026 results, keeps 4Q BLA-related timelines for detalimogeneSep 8Quarterly updateenGene, Inc.
FDA approves efficacy supplement for Eli Lilly's Retevmo (selpercatinib)Jul 14Regulatory decisionEli LillyenGene, Inc.
Sign in